NASDAQ$CYRX

CryoPort Inc. · Q1 2022 earnings

Q1 2022 earnings · · Investor relations

Briefing

Announced financial results for the first quarter of 2022, impacted by a fire at the New Prague manufacturing plant.

Cryoport reported its Q1 2022 results, noting that revenue was adversely impacted by approximately $9.4 million due to a fire at their New Prague, MN manufacturing plant. Despite this, the company supported a record 609 clinical trials in regenerative medicine and closed the quarter with approximately $600 million in cash and cash equivalents.

  • Biopharma/Pharma revenue was $43.0 million, up from $42.4 million in Q1 2021.
  • Revenue from commercial therapies grew 53.5% to a record $3.9 million.
  • The company supports a record 609 clinical trials in regenerative medicine.
  • Animal Health revenue decreased 24% to $6.8 million due to the fire at the New Prague manufacturing plant.

Headline financials

Total Revenue

$52.3M

Previous: $53.3M-1.8%
EPS (adj)

-$0.31

Previous: -$0.13-138.5%
Capital Expenditures

-$4.25M

Previous: -$2.81M-51.0%
Free Cash Flow

-$17.6M

Previous: -$6.34M-178.5%
Net Income

-$13.4M

Previous: -$3.53M-280.0%
Operating Income

-$7.82M

Previous: -$1.14M-584.7%
Gross Profit

$22.3M

Previous: $24.6M-9.0%
Cash & Equivalents

$134M

Previous: $85.5M+57.3%
Total Assets

$1.08B

Previous: $820M+31.9%
Stock-Based Comp

$4.13M

Previous: $2.99M+38.0%

Revenue & EPS history

CryoPort · Revenue · Quarterly

$52.3M

Q1 2022-1.8%vs Q1 2021
Beat estimate in 11 of 16 quarters(69%)
ActualEstimate

Forward guidance

The company is providing full year 2022 revenue guidance of $260 - $265 million, representing an increase of approximately 17% to 19% over 2021 revenue.

Tailwinds

  • Record backlog for cryogenic freezer and shipper systems and solutions.
  • Growth from support of clinical trials.
  • Growth from commercially launched therapies from cell and gene therapy clients.
  • Growth in temperature-controlled logistics and transport.
  • Expanded client utilization of new and expanding biostorage services.

Headwinds

  • Ongoing and prolonged COVID-19 pandemic.
  • Supply chain constraints.
  • Inflationary pressures.
  • Factors outside of our control.
  • Factors described in the Company’s filings with the Securities and Exchange Commission

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2022

Historical avgQ1 2022

+2.2%

Avg return

Earnings day

+2.5%

Avg return

5 days after

+8.5%

Avg return

30 days after

49%

28 / 57 earnings

Positive

+31.6%

Q4 2013

Best reaction

-33.8%

Q3 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+19.4%+33.2%+58.2%
Q4 2025+2.9%-4.7%+3.3%
Q3 2025-8.2%-7.4%+3.5%
Q1 2025+23.4%+23.3%+23.7%
Q4 2024+30.6%-7.1%+5.7%
Q3 2024-3.6%-0.9%-8.6%
Q2 2024+3.9%+10.0%+9.8%
Q1 2024-17.5%-16.7%-30.6%
Q4 2023-12.3%-7.3%+10.3%
Q3 2023+8.9%+8.4%+46.7%
Q2 2023-0.2%+1.2%-5.0%
Q1 2023+13.9%+4.5%-6.3%
Q4 2022+13.7%+9.9%+15.3%
Q3 2022-33.8%-35.7%-26.5%
Q2 2022+6.8%+5.2%-16.1%
Q1 2022-8.5%-14.6%-2.8%
Q4 2021+9.3%+7.0%+1.9%
Q3 2021-1.0%-1.2%-22.8%
Q2 2021-1.5%-3.6%+2.9%
Q1 2021+9.0%+11.6%-2.4%
Q4 2020-0.7%-11.7%-12.5%
Q3 2020+5.0%+24.2%+12.8%
Q2 2020-2.0%-5.0%+55.5%
Q1 2020+2.0%+17.0%+22.6%
Q4 2019+2.1%+0.8%-11.9%
Q3 2019+1.4%+3.9%+5.6%
Q2 2019+19.7%+24.5%+2.3%
Q1 2019+12.5%+12.5%+17.7%
Q4 2018-0.6%+6.6%+22.3%
Q3 2018-1.0%-9.4%-2.0%
Q2 2018-1.6%-14.7%-6.5%
Q1 2018+11.8%+23.0%+67.4%
Q4 2017+3.8%+6.4%-7.0%
Q3 2017-15.1%-22.9%-10.5%
Q2 2017-2.0%+3.6%+28.6%
Q1 2017+8.2%+9.0%+46.9%
Q4 2016+23.7%+9.0%+23.7%
Q2 2016-7.5%
Q1 2016+10.2%
Q4 2015-3.0%
Q3 2015+7.5%
Q2 2015-14.4%
Q1 2015-2.2%
Q4 2014+6.4%
Q3 2014-5.6%
Q4 2013+31.6%
Q3 2013-8.0%
Q2 2013+5.3%
Q1 2013+0.0%
Q4 2012-3.1%
Q3 2012-10.8%
Q2 2012-8.0%
Q1 2012-2.7%
Q1 2010+11.2%
Q3 2009+1.4%
Q2 2009-2.8%
Q1 2009+0.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro